Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be greater then or equal to 18 years of age.~* Subject must have relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.~* Subject has an Eastern Cooperative Oncology Group performance score of less than or equal to 1.~* Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.~* Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.~Exclusion Criteria:~* Chronic lymphocytic leukemia or Small Lymphocytic Lymphoma subject has undergone an allogeneic or autologous stem cell transplant.~* Subject has uncontrolled autoimmune hemolytic anemia or thrombocytopenia.~* Subject has tested positive for human immunodeficiency virus.~* Seropositivity for hepatitis B surface antigen or hepatitis C virus antibody or ribonucleic acid.~* History of severe allergic or anaphylactic reactions to rituximab.~* Subject has received a live viral vaccine within 6 months prior to the first dose of study drug.~* Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.~* Subject has received any of the following within 14 days prior to the first dose of study drug, or has not recovered to less than grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy:~  * Any anti-cancer therapy including chemotherapy, immunotherapy, or radiotherapy;~ * Investigational therapy, including targeted small molecule agents.~* Subject has a cardiovascular disability status of New York Heart Association Class greater then or equal to 2. Class 2 is defined as cardiac disease in which subjects are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea or anginal pain.~* Subject has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.~* Subject has a history of other active malignancies other than CLL/SLL within the past 2 years prior to study entry, with the exception of:~  * Adequately treated in situ carcinoma of the cervix uteri;~ * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;~ * Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.~* Subject has malabsorption syndrome or other condition that precludes enteral route of administration.~* Subject exhibits evidence of other clinically significant ongoing or recent condition(s) including, but not limited to:~  * Ongoing systemic infection (viral, bacterial, or fungal);~ * Diagnosis of fever and neutropenia within 1 week prior to study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Based on this trial design, predict the completion outcome and termination type (if applicable).